Duration of illness, regional brain morphology and neurocognitive correlates in schizophrenia

Annals of the Academy of Medicine Singapore

Volumn 38, Issue 5, 2009, Pages 388-395

  Chan, Wai Yen ^a   Chia, Ming Ying ^a   Yang, Guo Liang ^b   Woon, Puay San ^a   Sitoh, Yih Yian ^c   Collinson, Simon Lowes ^d   Nowinski, Wieslaw Lucjan ^b   Sim, Kang ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Duration of illness; Grey matter; Magnetic resonance imaging; Voxel based morphometry

Indexed keywords

ADULT; ARTICLE; BRAIN REGION; COGNITION; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; SCHIZOPHRENIA;

EID: 67049119385     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Kraepelin E. Dementia Praecox and Paraphrenia. Edinburgh, UK: E & S Livingstone, 1919.
2. Gur, RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, et al. A follow-up magnetic resonance imaging study of schizophrenia. Arch Gen Psychiatry 1998;55:145-152
3. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: A longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003;60:585-594 (Pubitemid 36682316)
4. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2001;58:148-157 (Pubitemid 32142752)
5. Premkumar P, Kumari V, Corr PJJ, Sharma T. Frontal lobe volumes in schizophrenia: Effects of stage and duration of illness. J Psychiatr Res 2006;40:627-637 (Pubitemid 44333115)
6. Sapara A, Cooke M, Fannon D, Francis A, Buchanan RW, Anilkumar APP, et al. Prefrontal cortex and insight in schizophrenia: a volumetric MRI study. Schizophr Res 2007;89:22-34. (Pubitemid 44881313)
7. Molina V, Sanz J, Sarrame F, Benito C, Palomo T. Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients. Psychiatry Res 2004;131:45-56. (Pubitemid 38891793)
8. Lopez-Garcia P, Aizenstein HJ, Snitz BE, Walter RP, Carter CS. Automated ROI-based brain parcellation analysis of frontal and temporal brain volumes in schizophrenia. Psychiatry Res 2006;147:153-161 (Pubitemid 44397474)
9. van Haren NEM, Pol HEH, Schnack HG, Cahn W, Mandl RCW, Collins DC, et al. Focal gray matter changes in schizophrenia across the course of the illness - a 5-year follow-up study. Neuropsychopharmacology 2007;32:2057-2066 (Pubitemid 47417696)
10. Burke L, Androutsos C, Jogia J, Byrne P, Frangou S. The Maudsley early onset schizophrenia study: the effect of age of onset and illness duration on fronto-parietal gray matter. Eur Psychiatry 2008;23:233-236
11. Premkumar P, Fannon D, Kuipers E, Cooke MA, Simmons A, Kumari V. Association between a longer duration of illness, age and lower frontal lobe grey matter volume in schizophrenia. Behav Brain Res 2008;193:132-139
12. Hietala J, Cannon TD, van Erp TGM, Syvälahti E, Vilkman H, Laakso A, et al. Regional brain morphology and duration of illness in never-medicated first-episode patients with schizophrenia. Schizophr Res 2003;64:79-81. (Pubitemid 37153352)
13. Preuss UW, Zetzsche T, Jäger M, Groll C, Frodl T, Bottlender R, et al. Thalamic volume in first-episode and chronic schizophrenic subjects: a volumetric MRI study. Schizophr Res 2005;73:91-101. (Pubitemid 39574683)
14. Liddle PF, Morris DL. Schizophrenic syndromes and frontal lobe performance. Br J Psychiatry 1991;158:340-345
15. Goldberg TE, Hyde TM, Kleinman JE, Weinberger DR. Course of schizophrenia: neuropsychological evidence for a static encephalopathy. Schizophr Bull 1993;19:797-804. (Pubitemid 23339436)
16. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001;58:24-32. (Pubitemid 32057762)
17. DeLisi LE, Tew W, Xie S, Hoff AL, Sakuma M, Kushner M, et al. A prospective follow-up study of brain morphology and cognition in first episode schizophrenia patients: preliminary findings. Biol Psychiatry 2005;38:349-360
18. McClure RK, Phillips I, Jazayerli R, Barnett A, Coppola R, Weinberger DR. Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment. Psychiatry Res 2006;148:121-132 (Pubitemid 44750583)
19. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM IV Axis I Disorders - Patient Version (SCID-P). Washington DC: American Psychiatric Press, 1994.
20. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Schizophrenia. Washington, DC: American Psychiatric Press, 2004.
21. Kane JM, Aguglia E, Altamura AC, Ayuso-Gutierrez JL, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55-66. (Pubitemid 28012861)
22. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667 (Pubitemid 36750143)
23. Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill, 2005.
24. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26:839-851 (Pubitemid 40825026)
25. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
26. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289 (Pubitemid 34852226)
27. Lezak MD. Neuropsychological Assessment. 3rd ed. New York: Oxford University Press, 1995.
28. Conners CK. Conners' Continuous Performance Test II: Computer program for Windows (CPT II). Multi Health Systems Inc, 2000.
29. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test, Manual. Odessa, FL: Psychological Assessment Resources, 1993.
30. Wechsler D. Weschsler Adult Intelligence Scale-III. San Antonio, TX: The Psychological Corporation, 1997.
31. Bland JM, Altman DG. Transforming data. BMJ 1996;312:770. (Pubitemid 26091245)
32. Ananth H, Popescu I, Critchley HD, Good CD, Frackowiak RSJ, Dolan RJ. Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am J Psychiatry 2002;159:1497-1505 (Pubitemid 35006729)
33. Velakoulis D, Wood SJ, Smith DJ, Soulsby B, Brewer W, Leeton L, et al. Increased duration of illness is associated with reduced volume in right medial temporal/anterior cingulate grey matter in patients with chronic schizophrenia. Schizophr Res 2002;57:43-49 (Pubitemid 34886444)
34. Bartzokis G. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology 2002;27:672-683
35. Lenroot RK, Giedd JN. Brain development in children and adolescents: insights from anatomical magnetic resonance imaging. Neurosci Biobehav Rev 2006;30:718-729 (Pubitemid 44292283)
36. Tanskanen P, Ridler K, Murray GK, Haapea M, Veijola JM, Jääskeläinen E, et al. Morphometric brain abnormalities in schizophrenia in a population-based sample: relationship to duration of illness. Schizophr Bull 2008.
37. Whitford TJ, Grieve SM, Farrow TFD, Gomes L, Brennan J, Harris AWF, et al. Progressive grey matter atrophy over the first 2-3 years of illness in first-episode schizophrenia: a tensor-based morphometry study. Neuroimage 2006;32:511-519 (Pubitemid 44164627)
38. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008;34:354-366 (Pubitemid 351323347)
39. Lieberman J, Chakos M, Wu H, Alvir J, Hoffman E, Robinson D, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001;49:487-499 (Pubitemid 32226407)
40. Konick LC, Friedman L. Meta-analysis of thalamic size in schizophrenia. Biol Psychiatry 2001;49:28-38 (Pubitemid 32332951)
41. Wright IC, Rabe-Hesketh S, Woodruff PWR, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000;157:16-25. (Pubitemid 30027416)
42. Chakos MH, Liberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994;151:1430-1436 (Pubitemid 24301686)
43. Chakos MH, Shirakawa O, Lieberman J, Lee H, Bilder R, Tamminga CA. Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry 1998;44:675-684 (Pubitemid 28496782)
44. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 1999;156:1200-1204 (Pubitemid 29374879)
45. Tamagaki C, Sedvall GC, Jönsson EG, Okugawa G, Hall H, Pauli S, et al. Altered white matter/gray matter proportions in the striatum of patients with schizophrenia: a volumetric MRI study. Am J Psychiatry 2005;162:2315-2321 (Pubitemid 41740210)
46. Tauscher-Wisniewski S, Tauscher J, Logan J, Christensen BK, Mikulis DJ, Zipursky RB. Caudate volume changes in first episode psychosis parallel the effects of normal aging: a 5-year follow-up study. Schizophr Res 2002;58:185-188 (Pubitemid 35284509)
47. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res 1997;74:129-140 (Pubitemid 27315863)
48. Noga JT, Vladar K, Torrey EF. A volumetric magnetic resonance imaging study of monozygotic twins discordant for bipolar disorder. Psychiatry Res 2001;106:25-34. (Pubitemid 32174866)
49. Heckers S, Heinsen H, Heinsen Y, Beckmann H. Cortex, white matter, and basal ganglia in schizophrenia: a volumetric postmortem study. Biol Psychiatry 1991;29:556-566
50. Lauer M, Beckmann H. The human striatum in schizophrenia. I. Increase in overall relative striatal volume in schizophrenics. Psychiatry Res 1997;68:87-98.
51. Sim K, Cullen T, Ongur D, Heckers S. Testing models of thalamic dysfunction in schizophrenia using neuroimaging. J Neural Transm 2006;113:907-928 (Pubitemid 43962784)
52. Hugdahl K, Bodner T, Weiss E, Benke T. Dichotic listening performance and frontal lobe function. Cogn Brain Res 2003;16:58-65. (Pubitemid 36183541)
53. Knudsen EI. Fundamental components of attention. Annu Rev Neurosci 2007;30:57-78. (Pubitemid 47218751)
54. Salgado-Pineda P, Junqué C, Vendrel P, Baeza I, Bargalló N, Falcón C, et al. Decreased cerebral activation during CPT performance: structural and functional deficits in schizophrenic patients. NeuroImage 2004;21:840-847 (Pubitemid 38314945)
55. Løberg E-M, Jørgensen HA, Green MF, Rund BR, Lund A, Diseth Å, et al. Positive symptoms and duration of illness predict functional laterality and attention modulation in schizophrenia. Acta Psychiatr Scand 2006;113:322-331
56. Kurtz M. Neurocognitive impairment across the lifespan in schizophrenia: An update. Schizophr Res 2005;74:15-26. (Pubitemid 40203180)
57. Keefe RSE, Perkins DO, Gu H, Zipursky RB, Christensen BK Lieberman JA. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr Res 2006;88:26-35 (Pubitemid 44693238)
58. Nuechterlein KH. Vigilance in schizophrenia and related disorders. In: Steinhauer SR, Gruzelier JH, Zubin J, editors. Handbook of Schizophrenia. Vol 5. Neuropsychology, Psychophysiology and Information Processing. Amsterdam: Elsevier, 1991.
59. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994;20:31-46. (Pubitemid 24071091)
60. Chen WJ, Faraone SV. Sustained attention deficits as markers of genetic susceptibility to schizophrenia. Am J Med Genet Semin Med Genet 2000;97:52-57 (Pubitemid 30257326)
61. Asarnow RF, MacCrimmon DJ. Span of apprehension deficits during the postpsychotic stages of schizophrenia: A replication and extension. Arch Gen Psychiatry 1981;38:1006-1011 (Pubitemid 11061228)
62. Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 1984;10:160-203.
63. Orzack MH, Kornetsky C. Attention dysfunction in chronic schizophrenia. Arch Gen Psychiatry 1966;14:323-327
64. Chen WJ, Liu SK, Chang C-J, Lien Y-J, Chang Y-H, Hwu H-G. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry 1998;155:1214-1220 (Pubitemid 28402515)